Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA 1994 |
| gptkbp:ATCCode |
B01AB04
|
| gptkbp:CASNumber |
9041-08-1
|
| gptkbp:contraindication |
history of heparin-induced thrombocytopenia
active major bleeding |
| gptkbp:genericName |
gptkb:dalteparin
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fragmin
|
| gptkbp:indication |
extended treatment of symptomatic venous thromboembolism in cancer patients
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Pfizer
|
| gptkbp:mechanismOfAction |
gptkb:anticoagulant
low molecular weight heparin |
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
subcutaneous injection
|
| gptkbp:sideEffect |
bleeding
injection site reaction thrombocytopenia |
| gptkbp:usedFor |
treatment of deep vein thrombosis
treatment of pulmonary embolism prevention of deep vein thrombosis prevention of pulmonary embolism prevention of clotting in hemodialysis treatment of non-Q-wave myocardial infarction treatment of unstable angina |
| gptkbp:bfsParent |
gptkb:dalteparin
|
| gptkbp:bfsLayer |
7
|